![Hong Bo Lu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hong Bo Lu
Direktor/Vorstandsmitglied bei
ARROWHEAD PHARMACEUTICALS, INC.
Vermögen: 4 Mio $ am 31.08.2026
Profil
Dr. Hong Bo Lu is an Independent Director at Arrowhead Pharmaceuticals, Inc., a Co-Founder & Managing Partner at NEXTBio Capital Management LP and an Independent Non-Executive Director at Zenas BioPharma, Inc. She is on the Board of Directors at Arrowhead Pharmaceuticals, Inc., Zenas BioPharma, Inc., Centrexion Therapeutics Corp., Abbott Pharmaceuticals (Shanghai) Co., Ltd., Beijing PINS Medical Co., Ltd., Pins Medical, Inc., Rarestone Group, Rgenta Therapeutics, Inc., Ronovo Surgical (Shanghai) Medical Science & Technology Ltd., Shanghai Rarestone Health Tech Group Co., Ltd., Visirna Therapeutics, Inc., Vivo Co-Invest (S) LP, Wuhan Createrna Science & Technology Co., Ltd. and Zenas BioPharma (USA) LLC.
Dr. Lu was previously employed as a Managing Partner by Vivo Capital LLC, an Independent Director by Terns Pharmaceuticals, Inc., an Independent Director by Avedro, Inc., an Independent Non-Executive Director by Turning Point Therapeutics, Inc., a Managing Partner by Lilly Asia Ventures, a Non-Executive Director by Echosens SA, a Managing Director by OrbiMed Advisors LLC, and a Senior Research Analyst by Piper Sandler & Co. (Broker).
She also served on the board at ADARx Pharmaceuticals, Inc., Beijing Anshi Biological Technology Co., Ltd., Blossomhill Therapeutics, Inc., Crown Bioscience International, Crown Bioscience, Inc., Elpiscience Biopharma Ltd., Geneception, Inc., Passage Bio, Inc. and RiboX Therapeutics, Inc. She received her undergraduate degree from Tsinghua University, a graduate degree from Tsinghua University, an MBA from Haas School of Business and a doctorate degree from the University of Washington.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.05.2026 | 52 012 ( 0,04 % ) | 4 Mio $ | 31.08.2026 | |
-.--% | 15.06.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
Aktive Positionen von Hong Bo Lu
| Unternehmen | Position | Beginn |
|---|---|---|
| CENTREXION THERAPEUTICS CORPORATION | Direktor/Vorstandsmitglied | 01.01.2019 |
| ARROWHEAD PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.04.2024 |
Zenas Pharma, Inc.
 Zenas Pharma, Inc. BiotechnologyHealth Technology Develops and markets immunology based therapies for patients | Direktor/Vorstandsmitglied | - |
Vivo Co-Invest (S) LP | Direktor/Vorstandsmitglied | - |
Ronovo Surgical (Shanghai) Medical Science & Technology Ltd.
 Ronovo Surgical (Shanghai) Medical Science & Technology Ltd. Medical SpecialtiesHealth Technology Manufactures surgical robots | Direktor/Vorstandsmitglied | - |
Rgenta Therapeutics, Inc.
 Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pipeline of oral and small-molecule RNA-targeting medicines | Direktor/Vorstandsmitglied | - |
Ablaze Pharmaceuticals
 Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of radiopharmaceutical therapies to treat cancer patients | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Hong Bo Lu
| Unternehmen | Position | Ende |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 05.05.2026 |
LAV Management Co., Ltd.
 LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Corporate Officer/Principal | 31.12.2020 |
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Hong Bo Lu
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
82
Beziehungen ersten Grades
31
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 31 |
|---|---|
Arrowhead Pharmaceuticals, Inc.
 Arrowhead Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drugs to treat intractable diseases | Health Technology |
OrbiMed Advisors LLC
 OrbiMed Advisors LLC Investment ManagersFinance OrbiMed generally seeks long-term capital appreciation through investments in companies in the global healthcare sector. | Finance |
Vivo Capital LLC
 Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life science sectors. It provides financing for early stage, growth stage, buyouts, spin-offs and restructurings. The firm also acquires controlling interest. It acts as lead investor and also makes co-investments. | Finance |
Piper Sandler & Co. (Broker)
 Piper Sandler & Co. (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Avedro, Inc.
 Avedro, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic pharmaceuticals & medical devices | Health Technology |
Crown Bioscience, Inc.
 Crown Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a global contract research organization for drug discovery | Commercial Services |
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops therapies for chronic pain and autoimmune disease | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Echosens SA
 Echosens SA Medical SpecialtiesHealth Technology Designs and markets medical imaging equipment for liver | Health Technology |
Tsinghua University
 Tsinghua University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV invests in companies located in China and the United States. The firm targets companies operating in the fields of biopharmaceuticals, human therapeutics, medical devices and diagnostics. It provides financing for seed, early and later stage capital requirements. | Finance |
Haas School of Business
 Haas School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Crown Bioscience International
 Crown Bioscience International BiotechnologyHealth Technology Operates as a biotechnology company that develops drug for oncology and metabolic diseases | Health Technology |
Beijing PINS Medical Co., Ltd.
 Beijing PINS Medical Co., Ltd. Medical SpecialtiesHealth Technology Develops single-channel implantable deep brain electrical stimulation pulse generator kit | Health Technology |
Terns Pharmaceuticals, Inc.
 Terns Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small-molecule product candidates to address serious diseases including oncology and obesity | Health Technology |
Elpiscience Biopharma Ltd.
 Elpiscience Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Develops cutting-edge immunotherapies to fight cancer | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage pipeline that develops RNA medicines for diseases | Commercial Services |
Rgenta Therapeutics, Inc.
Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pipeline of oral and small-molecule RNA-targeting medicines | Health Technology |
Geneception, Inc.
 Geneception, Inc. BiotechnologyHealth Technology Engages in research and development of biotechnology products | Health Technology |
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
Ronovo Surgical (Shanghai) Medical Science & Technology Ltd.
Ronovo Surgical (Shanghai) Medical Science & Technology Ltd. Medical SpecialtiesHealth Technology Manufactures surgical robots | Health Technology |
Pins Medical, Inc. | |
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of radiopharmaceutical therapies to treat cancer patients | Health Technology |
Beijing Anshi Biological Technology Co., Ltd.
 Beijing Anshi Biological Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in research, development and commercialization on cancer treatment | Health Technology |
Shanghai Rarestone Health Tech Group Co. Ltd.
 Shanghai Rarestone Health Tech Group Co. Ltd. Pharmaceuticals: MajorHealth Technology Develops and supplies rare disease pharmaceutical products & provides medical services | Health Technology |
Vivo Co-Invest (S) LP | |
RiboX Therapeutics, Inc.
 RiboX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops circular RNA therapeutics | Health Technology |
Zenas Pharma, Inc.
Zenas Pharma, Inc. BiotechnologyHealth Technology Develops and markets immunology based therapies for patients | Health Technology |
Visirna Therapeutics, Inc.
 Visirna Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Manufactures and commercializes RNAi-based investigational cardiometabolic medicines | Health Technology |
